Brokerages Set Affimed (NASDAQ:AFMD) Target Price at $16.00

Shares of Affimed (NASDAQ:AFMD) have been assigned an average rating of “Moderate Buy” from the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $16.00.

Several research analysts have weighed in on the company. Stifel Nicolaus cut their price objective on Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Affimed in a report on Friday, November 15th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th.

Institutional Trading of Affimed

A number of institutional investors have recently modified their holdings of the business. Choreo LLC purchased a new position in Affimed in the 2nd quarter valued at approximately $54,000. Intellectus Partners LLC boosted its holdings in shares of Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 10,250 shares during the period. Jane Street Group LLC purchased a new position in shares of Affimed in the third quarter valued at $44,000. FMR LLC raised its stake in shares of Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares in the last quarter. 30.82% of the stock is currently owned by hedge funds and other institutional investors.

Affimed Stock Down 1.0 %

Affimed stock opened at $2.84 on Friday. Affimed has a fifty-two week low of $2.61 and a fifty-two week high of $8.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93. The firm’s 50-day simple moving average is $3.31 and its 200 day simple moving average is $4.38.

Affimed (NASDAQ:AFMD) last posted its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.67 million. Affimed had a negative return on equity of 193.84% and a negative net margin of 7,836.26%. Equities analysts forecast that Affimed will post -4 EPS for the current fiscal year.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.